BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Life Science Pharmaceuticals, Inc. Enters Into Agreement with Abbott Laboratories (ABT) to Develop Antibody 806


11/17/2008 6:29:23 AM

GREENWICH, Conn.--(BUSINESS WIRE)--Life Science Pharmaceuticals, Inc. announced today that it has entered into a license agreement with Abbott to develop Antibody 806, which may prove to be an important tool in the fight against cancer.

The agreement provides Abbott with exclusive worldwide rights to Antibody 806, which targets the clinically validated pathway involving the Epidermal Growth Factor receptor (EGFr). Antibody 806 is differentiated by its unique epitope targeting a transitional form of EGFr. Financial details of the agreement were not disclosed.

Antibody 806 has demonstrated the ability to target and bind to EGFr while showing essentially no targeting of normal tissues. Applications for 806 include multiple forms of cancer and certain non-cancerous diseases. The 806 antibody was generated by Dr. Lloyd Old and his team at the New York Branch of the Ludwig Institute for Cancer Research (LICR). The antibody was then characterized in conjunction with the LICR's Branches in New York, San Diego and Melbourne, Australia. The first-in-man clinical trial led by Dr Andrew Scott was sponsored and conducted by the LICR at its Melbourne Center.

“We are delighted to have Abbott as our development partner,” stated James Fiore, president and CEO of Life Science Pharmaceuticals. “We are very impressed with the company’s technological capabilities and its commitment to developing class-leading antibodies.”

About Life Science Pharmaceuticals

Life Science Pharmaceuticals, Inc. (LSP) is a biopharmaceutical company dedicated to developing drugs for unmet or underserved medical needs. LSP and the Ludwig Institute for Cancer Research have entered into a strategic collaboration to develop cancer therapeutics. LSP monoclonal antibodies targeting melanoma and colon cancer are currently in clinical development. LSP continually seeks to acquire novel, early-stage product candidates for pre-clinical and clinical development.

Contact:

Life Science Pharmaceuticals, Inc. James Fiore, President, 203-422-6500 Jfiore@Investinlife.com

Source: Life Science Pharmaceuticals, Inc.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES